P2X3 Receptor Antagonists for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and specific agonists and antagonists for P2X receptor subtypes, particularly P2X3, which are crucial for regulating pain and other physiological processes, due to susceptibility to enzymatic degradation and the lack of receptor subtype-specific compounds.
Innovation Solution
Development of novel P2X3 receptor antagonists with specific structural formulas, including pharmaceutically acceptable salts and enantiomers, to modulate P2X3 receptors and treat pain-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If purinergic ligands are used to evaluate P2X receptor subtypes, then receptor function can be studied, but the ligands are susceptible to enzymatic degradation and lack subtype specificity
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of purinergic ligands through systematic variation of substituents at specific positions (R1-R6) to create compounds with enhanced stability and P2X3 receptor subtype specificity. This involves changing physical and chemical parameters such as molecular weight, lipophilicity, and steric hindrance to optimize both stability and selectivity
Solution Approach 2:
The patent employs composite materials by combining the purine core structure with various heterocyclic substituents (pyridyl, pyrimidinyl, triazolyl groups) to create hybrid molecules that exhibit both improved enzymatic stability and selective binding to P2X3 receptors. These composite structures integrate multiple functional moieties that work synergistically to achieve the desired pharmacological properties
2Reliability
If ATP is used to activate P2X3 receptors, then pain sensation can be evoked, but ATP is rapidly degraded by extracellular nucleotidases
Solution Approach 1:
The patent applies this principle by designing ligands that, while structurally complex, serve as effective short-acting agonists that rapidly activate P2X3 receptors before being degraded. The compounds are optimized to maximize their brief window of activity, achieving potent analgesic effects through high efficacy rather than prolonged duration
Solution Approach 2:
The patent modifies the chemical parameters of ATP by replacing labile functional groups with more stable isosters and adding protective substituents that resist enzymatic hydrolysis while maintaining receptor binding affinity, thereby extending the duration of action
3Object-affected harmful factors
If non-selective P2X antagonists are used, then pain can be blocked, but other P2X receptor subtypes are also inhibited causing off-target effects
Solution Approach 1:
The patent applies local quality by introducing specific substituents at particular positions on the purine ring system that create steric and electronic characteristics selective for P2X3 receptor binding. These localized modifications enhance affinity for P2X3 while reducing interaction with P2X1, P2X2, and other subtypes
Solution Approach 2:
The patent uses structure-activity relationship studies as an intermediary approach, systematically testing various substituent patterns to identify structural features that mediate selective P2X3 binding. This intermediate optimization process allows refinement of compound selectivity before clinical evaluation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively block P2X3 receptor activation, providing analgesic effects and treating pain, inflammatory pain, and tissue injury pain, while also being useful for genitourinary, gastrointestinal, and respiratory diseases.
Implementation Method 1
P2x3 receptor antagonists for treatment of pain... These compounds effectively block P2X3 receptor activation
Data Source
AI summary
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.